Vani Bremjit
Family Medicine · Yakima, WANPI 1568471589
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 686 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 54 manufacturers reported payments, led by AstraZeneca at 26.2% of the total. Among family medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 686 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Pfizer$1K
- AbbVie$1K
- GSK$847
- Boehringer Ingelheim$835
- Johnson & Johnson$622
- plus $5K from 48 others
What the payments were for
- Food & beverage$13,69699%
- Education$1861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,883 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $102,822 |
| FarxigaDapagliflozin Propanediol | 55 | $44,943 |
| OzempicSemaglutide | 32 | $34,121 |
| XareltoRivaroxaban | 15 | $21,639 |
| JardianceEmpagliflozin | 21 | $18,947 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $18,744 |
| JanuviaSitagliptin Phosphate | 11 | $17,063 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,184 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,671 |
| MyrbetriqMirabegron | 11 | $4,650 |
| PremarinEstrogens, Conjugated | 11 | $4,443 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $4,419 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $4,253 |
| Duloxetine Hcl | 155 | $4,250 |
| Atorvastatin Calcium | 468 | $3,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $1,433 | $107,266118 claims |
| AstraZenecaFarxiga, Symbicort | $3,642 | $48,35170 claims |
| Novo NordiskOzempic | $504 | $34,12132 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $847 | $24,41534 claims |
| Johnson & JohnsonXarelto | $622 | $21,63915 claims |
| Boehringer IngelheimJardiance | $835 | $18,94721 claims |
| MerckJanuvia | $11 | $17,06311 claims |
| Astellas Pharma US IncMyrbetriq | $531 | $4,65011 claims |
| AbbVieSynthroid | $1,081 | $1,90924 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $1,691199 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Yakima
- Theodore VyeYakima$17K
- Portia JonesYakima$16K
- John LyzanchukYakima$11K
- Roy GondoYakima$10K
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
- Marshall BrownPasco$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.